Global Liquid Biopsy Market will increase at a CAGR of 24.2%, from 2017 – 2022

The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.

Report Includes

-An overview of the global markets for liquid biopsy research tools, services, and diagnostics

-Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022

-Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration

-Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, and research tools reagents

-Breakdowns of the market by product, product type, application, end use industry, technology, and indication

-Evaluation of the market’s dynamics, specifically growth drivers, restraints, and opportunities

-Profiles of major players in the industry

Request Sample copy of Global Liquid Biopsy Market Report at :

Study Goals and Objectives

It’s goal for this study is to provide an in-depth update study of the liquid biopsy diagnostics industry, an emerging industry with high market potential. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geography. The market sizes are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

Market segments that provide exceptional growth opportunities include cancer therapy guidance and monitoring and organ transplant surveillance.

The report provides a comprehensive discussion of liquid biopsy technologies, clinical applications, industry structure, liquid biopsy funding initiatives, global markets, patent status and companies. The report is designed to provide an in-depth analysis of the industry and markets and aid companies in their strategic planning efforts relating to life science tools and diagnostics.

Reasons for Doing This Study

Traditional biopsy methods are often invasive, uncomfortable and carry risks of side effects. Liquid biopsy addresses these issues because it is noninvasive and carries little, if any, side effect risks.

In the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to screen, monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability and thus is of high interest to the medical community.

Liquid-biopsy-enabling technologies are coming to the forefront and provide significant market growth momentum to the industry. Downstream analysis technologies like next-generation sequencing and digital polymerase chain reaction (PCR) are progressing in capabilities, efficiency, and costs. Upstream technologies like microfluidics, cell-free deoxyribo nucleic acid (DNA) capture and isolation, cell capture, and DNA amplification are also making significant progress.

To see the full report, click the link below :

About Bharat Book Bureau :
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry analysis, country reports, business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Follow us on : Twitter, Facebook, Linkedin, Google Plus

Designed by
Powered by
%d bloggers like this: